Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesBariatric & Obesity ManagementCVS Caremark Zepbound Prior Auth Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 6192-C

    Initial Prior Authorization with Quantity Limit Zepbound Weight Loss Management

    Customize your policy alerts

    Sign up for cvs_caremark Policy 6192-C alerts

    Get alerted when Policy 6192-C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs initial and continuation prior authorization, quantity limits, and approval durations for Zepbound (tirzepatide) in adults with obesity or overweight-related weight management needs and adults with obesity and moderate to severe obstructive sleep apnea. Coverage requires specified clinical criteria, documentation, reduced-calorie diet, and increased physical activity.

    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization with Quantity Limit Zepbound Weight Loss Management
    Policy CodePolicy 6192-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the established moderate to severe OSA diagnosis, AHI of at least 15 events per hour, and technically adequate PSG or HSAT results for approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2FDA-approved covered indication pathways
    AHI ≥15Minimum AHI for OSA coverage
    BMI ≥30BMI threshold for obesity-based eligibility
    6 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Weight management program before initial therapy
    5%Weight response for continuation
    21/63 daysQuantity-limit processing durations

    Coverage Criteria

    Initial Therapy — Obstructive Sleep Apnea

    Covered when the requested drug is used with a reduced-calorie diet and increased physical activity and all criteria are met.

    Initial therapy for obstructive sleep apnea

    • Required OSA criteria

      • The patient has an established diagnosis of moderate to severe obstructive sleep apnea with an apnea-hypopnea index (AHI) of at least 15 events per hour on polysomnography (PSG) or home sleep apnea test (HSAT) with a technically adequate device.AHI >=15 events/hour

        Documentation is required for approval.

      • The patient has a current body mass index (BMI) greater than or equal to 30 kg/m2.BMI >=30 kg/m2

        Documentation is required for approval.

    Initial Therapy — Reduction in Excess Body Weight or Long-Term Maintenance

    Covered when the requested drug is used with a reduced-calorie diet and increased physical activity and all criteria are met.

    Initial therapy for reduction in excess body weight or long-term maintenance

    • The patient has participated in a comprehensive weight management program that encourages behavioral modification, a reduced-calorie diet, increased physical activity, and continuing follow-up for at least 6 months before using drug therapy.>=6 months
    • ONE of

      • The patient has a baseline BMI greater than or equal to 30 kg/m2.BMI >=30 kg/m2

        Documentation is required for approval.

      • ALL of the following

    Continuation Therapy — Obstructive Sleep Apnea

    Covered when the requested drug is used with a reduced-calorie diet and increased physical activity and all criteria are met.

    Continuation therapy for obstructive sleep apnea

    • The patient has an established diagnosis of moderate to severe obstructive sleep apnea with an apnea-hypopnea index (AHI) of at least 15 events per hour on polysomnography (PSG) or home sleep apnea test (HSAT) with a technically adequate device.AHI >=15 events/hour

      Documentation is required for approval.

    • The patient has achieved or maintained a positive response to treatment from baseline, evidenced by a decrease in OSA symptoms.Decrease in OSA symptoms
    • The patient is being treated with a maintenance dosage of the requested drug based on individual treatment response and tolerability.

    Continuation Therapy — Reduction in Excess Body Weight or Long-Term Maintenance

    Covered when the requested drug is used with a reduced-calorie diet and increased physical activity and all criteria are met.

    Continuation therapy for reduction in excess body weight or long-term maintenance

    • The patient has completed at least 3 months of therapy with the requested drug at a stable maintenance dose.>=3 months
    • ONE of

      • The patient has lost at least 5 percent of baseline body weight.>=5% loss of baseline body weight

        Documentation is required for approval.

      • The patient has continued to maintain the initial 5 percent weight loss.Maintenance of initial 5% weight loss

    Vials are covered under the LillyDirect manufacturer program and are not included among the products covered by this document. Over-the-counter (OTC) products are not included unless otherwise stated.

    Clinical Thresholds and Coding Reference

    OSA Apnea-Hypopnea Index
    Minimum AHIAt least 15 events per hour
    Applies toModerate to severe obstructive sleep apnea
    Measurement contextThe AHI must be established through polysomnography or a home sleep apnea test using a technically adequate device
    Current BMI for OSA
    Qualifying current BMIGreater than or equal to 30 kg/m2
    Applicable pathwayInitial and continuation treatment of moderate to severe obstructive sleep apnea in an adult with obesity
    Documentation

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Initial Therapy Authorization

    Prior authorization is required for initial therapy. Authorization may be granted when Zepbound is used with a reduced-calorie diet and increased physical activity for either moderate-to-severe OSA in an adult with obesity or weight management in an adult meeting the applicable eligibility criteria.

    • For OSA: documented moderate-to-severe OSA with AHI ≥15 events per hour and current BMI ≥30 kg/m².
    • For weight management: participation in a comprehensive behavioral weight-management program with a reduced-calorie diet, increased physical activity, and continuing follow-up for at least 6 months; plus either baseline BMI ≥30 kg/m² or baseline BMI ≥27 kg/m² with at least one weight-related comorbidity.
    Prior Authorization

    Continuation Therapy Authorization

    Continuation authorization requires documented ongoing clinical benefit. Zepbound must continue to be used with a reduced-calorie diet and increased physical activity for the applicable OSA or weight-management indication.

    • For OSA: the patient must have an established diagnosis with AHI ≥15, demonstrate a positive response from baseline evidenced by decreased OSA symptoms, and be receiving a maintenance dosage based on individual treatment response and tolerability.

    Clinical Background

    Zepbound (tirzepatide) is indicated for use with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults who are overweight and have at least one weight-related comorbidity. It is also indicated to treat moderate to severe obstructive sleep apnea in adults with obesity. Coverage review addresses separate initial and continuation therapy pathways for weight management and obstructive sleep apnea.

    Key Definitions

    Moderate to Severe Obstructive Sleep Apnea
    DefinitionModerate to severe obstructive sleep apnea is established by an apnea-hypopnea index of at least 15 events per hour
    Acceptable testingPolysomnography (PSG) or a home sleep apnea test (HSAT)
    Testing standardTesting must use a technically adequate device
    Comprehensive Weight Management Program
    Behavioral componentEncourages behavioral modification
    Lifestyle componentsIncludes a reduced-calorie diet and increased physical activity
    Follow-up
    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization with Quantity Limit Zepbound Weight Loss Management
    Policy CodePolicy 6192-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the established moderate to severe OSA diagnosis, AHI of at least 15 events per hour, and technically adequate PSG or HSAT results for approval.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Coding ReferenceAuthorization, Documentation, and Denial RisksClinical BackgroundKey Definitions
    The patient has a baseline BMI greater than or equal to 27 kg/m2.BMI >=27 kg/m2

    Documentation is required for approval.

  1. The patient has at least one weight-related comorbid condition, such as hypertension, type 2 diabetes mellitus, or dyslipidemia.>=1 weight-related comorbid condition

    Documentation is required for approval. For patients transitioning from another drug therapy for weight loss, consider the comorbid condition(s) at the start of any drug therapy.

  2. Documentation is required for approval.

    Current BMI documentation is required for approval
    Baseline BMI for Weight Management
    Obesity pathwayBaseline BMI greater than or equal to 30 kg/m2
    Overweight pathwayBaseline BMI greater than or equal to 27 kg/m2 with at least one weight-related comorbid condition
    Examples of comorbid conditionsHypertension, type 2 diabetes mellitus, or dyslipidemia
    Prior Comprehensive Weight Management Program
    Required durationAt least 6 months before drug therapy
    Program requirementsBehavioral modification, a reduced-calorie diet, increased physical activity, and continuing follow-up
    Transitioning from another weight-loss drugAssess baseline BMI and weight-related comorbid conditions at the start of any drug therapy
    Continuation Weight Response
    Required weight responseAt least 5% loss of baseline body weight or maintenance of the initial 5% weight loss
    Stable maintenance treatmentAt least 3 months of therapy with the requested drug at a stable maintenance dose
    DocumentationWeight response documentation is required for approval
  3. For weight management: the patient must have completed at least 3 months of therapy at a stable maintenance dose and either lost at least 5% of baseline body weight or maintained the initial 5% weight loss.
  4. Note

    Approval Duration

    Approval duration differs by indication and therapy phase.

    • Obstructive sleep apnea: initial therapy—6 months; continuation therapy—12 months.
    • Reduction in excess body weight or long-term maintenance of weight reduction: initial therapy—8 months; continuation therapy—12 months.
    • Policy reference: 6192-C.
    Denial Risk

    Concurrent Incretin Therapy

    Coadministration of Zepbound with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.

    • Review the complete medication regimen before requesting or continuing therapy.
    • Concurrent use may create a coverage or authorization issue because it is outside the policy limitation of use.
    Documentation Required

    Baseline BMI and Comorbidity Documentation

    Document the baseline weight-management eligibility data used for the authorization request, including BMI and applicable comorbidities.

    • Document baseline BMI ≥30 kg/m²; or baseline BMI ≥27 kg/m² plus at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia.
    • For patients transitioning from another weight-loss drug, use and document BMI at the start of any drug therapy.
    • For transitioning patients, document the applicable weight-related comorbidity or comorbidities present at the start of any drug therapy.
    Documentation Required

    OSA Diagnostic Documentation

    For OSA requests, submit documentation establishing moderate-to-severe OSA and the required diagnostic findings.

    • Document an established diagnosis of moderate-to-severe OSA.
    • Document AHI ≥15 events per hour.
    • Provide polysomnography (PSG) or a home sleep apnea test (HSAT) performed with a technically adequate device.
    Documentation Required

    Current BMI Documentation

    Document the patient’s current BMI for OSA approval.

    • Current BMI must be ≥30 kg/m².
    • Documentation is required for approval.
    Documentation Required

    Continuation Weight-Response Documentation

    For continuation weight-management requests, document treatment duration, maintenance dosing, and the patient’s weight response.

    • Document at least 3 months of therapy with Zepbound at a stable maintenance dose.
    • Document either loss of at least 5% of baseline body weight or continued maintenance of the initial 5% weight loss.
    Denial Risk

    OSA Diagnostic or BMI Criteria Not Met

    Initial OSA authorization is at risk of denial when the required diagnosis, diagnostic testing, AHI, or current BMI is missing or insufficient.

    • Deny or do not approve when moderate-to-severe OSA is not established or AHI is <15 events per hour.
    • Deny or do not approve when PSG or HSAT documentation is absent or the device is not technically adequate.
    • Deny or do not approve when current BMI is <30 kg/m² or current BMI documentation is not provided.
    Denial Risk

    Initial Weight-Management Criteria Not Met

    Initial weight-management authorization is at risk of denial when the required comprehensive program or eligibility criteria are not met.

    • Deny or do not approve when the patient has not completed at least 6 months of a comprehensive program including behavioral modification, reduced-calorie diet, increased physical activity, and continuing follow-up.
    • Deny or do not approve when baseline BMI is <30 kg/m² without the alternative qualification of baseline BMI ≥27 kg/m² plus a qualifying weight-related comorbidity.
    • Deny or do not approve when required baseline BMI, comorbidity, or transition documentation is missing.
    Denial Risk

    Continuation Response Criteria Not Met

    Continuation authorization is at risk of denial when the patient does not demonstrate the required response or is not receiving an appropriate maintenance dose.

    • For OSA, deny or do not approve when the diagnosis or AHI ≥15 documentation is insufficient, OSA symptoms have not decreased from baseline, or the patient is not receiving a maintenance dosage based on response and tolerability.
    • For weight management, deny or do not approve when the patient has not completed at least 3 months at a stable maintenance dose or has not lost at least 5% of baseline body weight and has not maintained the initial 5% loss.
    • Ensure continuation requests include documentation supporting the applicable response and maintenance-dose requirements.
    Includes continuing follow-up
    Maintenance Dosage
    Individualized dosingA dose selected according to the patient's individual treatment response and tolerability
    Continuation requirementThe patient must be treated with a maintenance dosage of the requested drug
    Treatment contextMaintenance dosage is part of the continuation criteria for obstructive sleep apnea